Goal-oriented therapy with miglustat in Gaucher disease

References

• Charrow J, Andersson HC, Kaplan P, et al. The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med 2000;160:2835-43
   PubMed Web of Science ®Google Scholar
• Beutler E, Grabowski GA. Glycosylceramide lipidoses: Gaucher disease. In: Scriver CR, Beaudet AL, Sly WS, et al. eds. The Metabolic and Molecular Basis of Inherited Disease. New York: McGraw-Hill, 1995, pp. 2641–70
   Google Scholar
• Cox TM, Schofield JP. Gaucher's disease: clinical features and natural history. Baillieres Clin Haematol 1997;10:657-89
   PubMed Web of Science ®Google Scholar
• Mistry PK, Sirrs S, Chan A, et al. Pulmonary hypertension in type 1 Gaucher's disease: genetic and epigenetic determinants of phenotype and response to therapy. Mol Genet Metab 2002;77:91-8
   PubMed Web of Science ®Google Scholar
• Beutler E, Grabowski GA. Gaucher disease. In: Scriver CR, Beaudet AL, Sly WS, et al. eds. The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill, 2001, pp. 3635-68
   Google Scholar
• Hruska KS, LaMarca ME, Scott CR, et al. Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum Mut 2008;29:567-83
   PubMed Web of Science ®Google Scholar
• Pastores GM, Barnett NL, Bathan P, et al. A neurological symptom survey of patients with type I Gaucher disease. J Inherit Metab Dis 2003;26:641-5
   PubMed Web of Science ®Google Scholar
• Chérin P, Sedel F, Mignot C, et al. [Neurological manifestations of type 1 Gaucher's disease: is a revision of disease classification needed?] Rev Neurol (Paris) 2006;162:1076-83 (In French)
   PubMedGoogle Scholar
• Sidransky E. Gaucher disease: complexity in a “simple” disorder. Mol Genet Metab 2004;83:6-15
   PubMed Web of Science ®Google Scholar
• Hollak CE, Biegstraaten M Van Schaik, in et al. Prevalence of polyneuropathy in adult Type 1 Gaucher disease (GD1): a multinational prospective observational study. Poster presented at the 2007 Annual Congress of the Society of the Study of Inborn Errors of Metabolism (SSIEM), Hamburg, Germany, September 4–7
   Google Scholar
• Pastores GM, Weinreb NJ, Aerts H, et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 2004;41( Suppl. 5):4-14
   PubMed Web of Science ®Google Scholar
• Genzyme Corporation. Cerezyme® (imiglucerase for injection) Prescribing Information. Available at: http://www.cerezyme.com/global/pi.pdf [Last accessed 18 July 2008]
   Google Scholar
• Platt FM, Neises GR, Dwek RA, et al. N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. J Biol Chem 1994;269:8362-5
   PubMed Web of Science ®Google Scholar
• Miglustat Summary of Product Characteristics. Available at: http://www.emea.europa.eu/humandocs/Humans/EPAR/zavesca/zavesca.htm [Last accessed 20 October 2008]
   Google Scholar
• Actelion Pharmaceuticals US, Inc. Zavesca® (miglustat capsules) Prescribing Information. Available at: http://www.zavesca.com/pdfs/zavesca_pi.pdf [Last accessed 18 July 2008]
   Google Scholar
• Cox T, Lachmann R, Hollak C, et al. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 2000;355:1481-5
   PubMed Web of Science ®Google Scholar
• Elstein D, Hollak C, Aerts JM, et al. Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. J Inherit Metab Dis 2004;27:757-66
   PubMed Web of Science ®Google Scholar
• Pastores GM, Barnett NL, Kolodny EH. An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment. Clin Ther 2005;27:1215-27
   PubMed Web of Science ®Google Scholar
• Pastores GM, Elstein D, Zimran A. Effect of miglustat on bone disease in adult type 1 Gaucher disease. Clin Ther 2007;29:1645-54
   PubMed Web of Science ®Google Scholar
• Giraldo P, Latre P, Alfonso P, et al. Short-term effect of miglustat in every day clinical use in treatment-naive or previously treated patients with type 1 Gaucher's disease. Haematologica 2006;91:703-6
   PubMed Web of Science ®Google Scholar
• Elstein D, Dweck A, Attias D, et al. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement. Blood 2007;110:2296-301
   PubMed Web of Science ®Google Scholar
• Wenstrup RJ, Roca-Espiau M, Weinreb NJ, et al. Skeletal aspects of Gaucher disease: a review. Br J Radiol 2002;75(Suppl. 1):2-12
   Web of Science ®Google Scholar
• Mankin HJ, Trahan CA, Barnett NA, et al. A questionnaire study for 128 patients with Gaucher disease. Clin Genet 2006;69:209-17
   PubMed Web of Science ®Google Scholar
• Kaplan P, Andersson HC, Kacena KA, et al. The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis. Arch Pediatr Adolesc Med 2006;160:603-8
   PubMed Web of Science ®Google Scholar
• Giraldo P, Solano V, Pérez-Calvo JI, et al. Quality of life related to type 1 Gaucher disease: Spanish experience. Qual Life Res 2005;14:453-62
   PubMed Web of Science ®Google Scholar
• Stowens DW, Teitelbaum SL, Kahn AJ, et al. Skeletal complications of Gaucher disease. Medicine 1985;64:310-22
   PubMed Web of Science ®Google Scholar
• Kolodny EH, Ullman MD, Mankin HJ, et al. Phenotypic manifestations of Gaucher disease clinical features in 48 biochemically verified Type 1 Gaucher patients and comment on Type 2 patients. In: Desnick RJ, Gatt S, Grabowski GA, eds. Gaucher Disease: a Century of Delineation and Research. New York: Alan R Liss, 1982, pp. 33-65
   Google Scholar
• Pastores GM, Wallenstein S, Desnick RJ, et al. Bone density in type I Gaucher disease. J Bone Miner Res 1996;11:1801-7
   PubMed Web of Science ®Google Scholar
• Javier RM, Hachulla E. Osteoarticular manifestations of Gaucher disease in adults: pathophysiology and treatment. Presse Med 2007;36:1971-84
   PubMed Web of Science ®Google Scholar
• Baldellou A, Andria G, Campbell PE, et al. Paediatric non-neuronopathic Gaucher disease: recommendations for treatment and monitoring. Eur J Pediatr 2004;163:67-75
   PubMed Web of Science ®Google Scholar
• vom Dahl S, Poll L, Di Rocco M, et al. Evidence-based recommendations for monitoring bone disease and the response to enzyme replacement therapy in Gaucher patients. Curr Med Res Opin 2006;22:1045-64
   PubMed Web of Science ®Google Scholar
• Maas M, Hangartner T, Mariani G, et al. Recommendations for the assessment and monitoring of skeletal manifestations in children with Gaucher disease. Skeletal Radiol 2008;37:185-8
   PubMed Web of Science ®Google Scholar
• Treiber A, Morand O, Clozel M. The pharmacokinetics and tissue distribution of miglustat in the rat. Xenobiotica 2007;37:298-314
   PubMed Web of Science ®Google Scholar
• Fukumoto S, Iwamoto T, Sakai E, et al. Current topics in pharmacological research on bone metabolism: osteoclast differentiation regulated by glycosphingolipids. J Pharmacol Sci. 2006;100:195-200
   PubMed Web of Science ®Google Scholar
• Mikosch P, Reed M, Baker C,, et al. Changes of bone metabolism in seven patients with Gaucher disease treated consecutively with imiglucerase and miglustat. Calcif Tissue Int 2008;83:43-54
   Google Scholar
• Hollak CEM, van Weely S, Maas M, et al. Bone disease and Zavesca™ (miglustat) – new insights and results. Poster presented at the 2004 Annual Congress of the Society of the Study of Inborn Errors of Metabolism (SSIEM), Amsterdam, The Netherlands, 31 August–3 September
   Google Scholar
• Aerts JM, Hollak CE, Boot RG, et al. Substrate reduction therapy of glycosphingolipid storage disorders. J Inherit Metab Dis 2006;29:449-56
   PubMed Web of Science ®Google Scholar
• Poll LW, Maas M, Terk MR, et al. Response of Gaucher bone disease to enzyme replacement therapy. Br J Radiol 2002;75(Suppl. 1):25-36
   Web of Science ®Google Scholar
• Roca M, Latre P, Alfonso C,, et al. Bone densitometry usefully in the evaluation of bone disease in type 1 Gaucher patients. A preliminary comparative study. Poster presented at the 2008 conference of the European Working Group on Gaucher Disease (EWGGD), Budapest, Hungary, 4-7 June
   Google Scholar
• Hayes RP, Grinzaid KA, Duffey EB, et al. The impact of Gaucher disease and its treatment on quality of life. Qual Life Res 1998;7:521-34
   PubMed Web of Science ®Google Scholar
• Weinreb NJ, Charrow J, Andersson HC, et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med 2002;113:112-9
   PubMed Web of Science ®Google Scholar
• Mehta A. Clinical experience with substrate reduction therapy. Eur J Intern Med 2006;17:13-15
   Web of Science ®Google Scholar
• Heitner R, Hrebicek M, Elstein C,, et al. An open-label study of 5-years treatment with miglustat in adult patients with type 1 Gaucher disease. Poster presented at the 54th Annual Meeting of the American Society of Human Genetics (ASH-G), New Orleans, USA, 9–13 October, 2006
   Google Scholar
• Hill SC, Reining JW, Barranger JA, et al. Gaucher disease: sonographic appearance of the spleen. Radiology 1986;160:631-634
   PubMed Web of Science ®Google Scholar
• Dawson A, Elias DJ, Rubenson D, et al. Pulmonary hypertension developing after alglucerase therapy in two patients with type 1 Gaucher disease complicated by the hepatopulmonary syndrome. Ann Intern Med 1996;125:901-4
   PubMed Web of Science ®Google Scholar
• Elstein D, Klutstein MW, Lahad A, et al. Echocardiographic assessment of pulmonary hypertension in Gaucher's disease. Lancet 1998;351:1544-6
   PubMed Web of Science ®Google Scholar
• Galiè N, Seeger W, Naeije R, et al. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2004;43(12 Suppl. S):81S-88S
   Web of Science ®Google Scholar
• Schiffmann R, Harris C, DeVile C, et al. Miglustat in Gaucher et al. disease Type 3: a randomized controlled study with a non-comparative extension phase. Ann Neurol 2008 (in press)
   Google Scholar
• Hollak CE, Maas M, Aerts JM. Clinically relevant therapeutic endpoints in type 1 Gaucher disease. J Inherit Metab Dis 2001;24( Suppl. 2):97-105
   PubMed Web of Science ®Google Scholar
• Lacerda L, Arosa FA, Lacerda R, et al. T-cell numbers relate to bone involvement in Gaucher disease. Blood Cells Mol Dis 1999;25:130-8
   PubMed Web of Science ®Google Scholar
• Boot RG, Verhoek M, de Fost M, et al. Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Blood 2004; 103:33-9
   PubMed Web of Science ®Google Scholar
• Hollak CE, van Weely S, van Oers MH, et al. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest 1994;93:1288-92
   PubMed Web of Science ®Google Scholar
• Korolenko TA, Zhanaeva SY, Falameeva OV, et al. Chitotriosidase as a marker of macrophage stimulation. Bull Exp Biol Med 2000;130:948-50
   PubMed Web of Science ®Google Scholar
• Hughes DA, Ginsberg L, Baker R, et al. Effective treatment of an elderly patient with Gaucher's disease and Parkinsonism: a case report of 24 months’ oral substrate reduction therapy with miglustat. Parkinsonism Relat Dis 2007;13:365-8
   PubMed Web of Science ®Google Scholar
• Hollak C, Hughes D, van Schaik IN,, et al. Miglustat (Zavesca) in type 1 Gaucher disease: results of a post-marketing surveillance programme. Poster presented at the 2008 conference of the European Working Group on Gaucher Disease (EWGGD), Budapest, Hungary, 4–7 June
   Google Scholar
• Batiecie L, Detel D, Varljen J. Age dependent changes in activity of intestinal disaccharidases and alkaline phosphatase activity in CD26 deficient mice. Croat Chem Acta 2008;81:59-65
   Web of Science ®Google Scholar
• Gebhard RL, Karouani R, Prigge WF, et al. The effect of severe zinc deficiency on activity of intestinal disaccharidases and 3-hydroxy-3-methylglutaryl coenzyme A reductase in the rat. J Nutr 1983;113:855-9
   PubMed Web of Science ®Google Scholar
• Cox TM, Aerts JM, Andria G, et al. The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. J Inherit Metab Dis 2003;26:513-26
   PubMed Web of Science ®Google Scholar
• Heitner R, Elstein D, Aerts J, et al. Low-dose N-butyldeoxynojirimycin (OGT 918) for type I Gaucher disease. Blood Cells Mol Dis 2002;28:127-33
   PubMed Web of Science ®Google Scholar
• Elstein D, Dweck A, Attias D, et al. Oral maintenance of miglustat in adult patients with type 1 Gaucher disease: the patients’ quality of life perspective. Poster presented at the 2007 Annual Congress of the Society of the Study of Inborn Errors of Metabolism (SSIEM), Hamburg, Germany, 4–7 September
   Google Scholar
• Wenstrup RJ, Bailey L, Grabowski GA, et al. Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapy. Blood 2004;104:1253-7
   PubMed Web of Science ®Google Scholar
• De Fost M, Hollak CEM, Groener JEM, et al. Superior effects of high dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels; a two center retrospective analysis. Blood 2006;108:830-5
   PubMed Web of Science ®Google Scholar
• Zimran A, Elstein D, Beutler E. Low-dose therapy trumps high-dose therapy again in the treatment of Gaucher disease. Blood 2006;108:802-3
   PubMed Web of Science ®Google Scholar
• Jaussaud R, Javier RM, Rose C,, et al. French Observatoire on Gaucher disease (FROG): results on 107 patients. Abstract presented at the 2007 Annual Congress of the Society of the Study of Inborn Errors of Metabolism (SSIEM), Hamburg, Germany, 4–7 September (422-P)
   Google Scholar